Pexiganan

Drug Profile

Pexiganan

Alternative Names: Cytolex; Locilex; MSI-78; Pexiganan acetate

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Genaera Corporation
  • Developer Dipexium Pharmaceuticals; Genaera Corporation; RRD International
  • Class Antibacterials; Antimicrobial cationic peptides; Peptide antibiotics
  • Mechanism of Action Cell membrane permeability enhancers; Defensin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic foot ulcer
  • Phase I Skin and soft tissue infections
  • Discontinued Impetigo

Most Recent Events

  • 28 Feb 2017 Dipexium Pharmaceuticals has patents pending for Pexiganan (Locilex®) in Brazil, Canada, China, Eurasia, Indonesia, Mexico, Singapore and South Africa (Dipexium Annual report 2016)
  • 07 Sep 2016 Dipexium Pharamaceuticals receives notice of allowance for patents related to pexiganan cream 0.8% in South Korea and Hong Kong
  • 07 Sep 2016 Dipexium Pharmaceuticals has patent protection for pexiganan cream 0.8% in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top